期刊文献+

Bevacizumab治疗湿性型年龄相关性黄斑变性疗效观察 被引量:1

Effect of Bevacizumab on Exudative Age-related Macular Degeneration
下载PDF
导出
摘要 目的探讨Bevacizumab治疗湿性型年龄相关性黄斑变性的效果。方法我院20例(20眼)湿性型年龄相关性黄斑变性患者给予玻璃体腔内注射Bevacizumab治疗,观察术前、术后1周及术后1个月矫正视力,术前及术后1个月视网膜中心厚度。结果术后1周及术后1个月矫正视力较术前明显升高,差异有统计学意义(P<0.05);术后1个月视网膜中心厚度较术前明显降低,差异有统计学意义(P<0.05)。术后1个月18眼染料渗漏减少,2眼渗漏无减少。所有注射眼均未发生眼内炎、青光眼、视网膜脱离及血管阻塞等严重并发症。结论玻璃体腔内注射Bev-acizumab治疗湿性型年龄相关性黄斑变性可以显著提高视力,减轻黄斑水肿。 Objective To investigate the clinical efficacy and validity of Bevacizumab in the treatment of exudative age-related macular degeneration(AMD).Methods Twenty eyes of 20 AMD patients received intravitreal injection of Bevacizumb(Avastin).The best-corrected visual acuity(BCVA) before and 1-week and 1-month after the operation,and the central retinal thickness (CRT) before and one month after the operation were retrospectively observed.Results The BCVA was obviously improved 1-week and 1-month after the operation as compared with pre-operation(P0.05).And the CRT 1-month after the operation decreased remarkably as compared with pre-operation(P0.05).less leakage on FFAICGA was observed in 18 eyes one month after the operation,and no obvious improvement on FFAICGA leakage was found in 2 eyes.No adverse events such as endophthalmitis,glaucoma,retinal detachment,and angiemphrasis were found.Conclusion Intravitreal Bevaciumab injection can remarkably improve visual acuity and reduce macular edema in the treatment of exudative AMD.
出处 《中国全科医学》 CAS CSCD 北大核心 2010年第24期2741-2743,共3页 Chinese General Practice
基金 河北省引进留学人员经费资助(冀人办[2007]20号)
关键词 黄斑变性 视力 治疗 Macular degeneration Vision low Theraphy
  • 相关文献

参考文献15

  • 1Mason AB,Hoe J.CCR3:shedding new light on a dark problem?[J].J Mol Cell Biol,2009,1(1):17-19.
  • 2Kourlas H,Abrams P.Ranibizumab for thetreatment of neovascular age-related macular dgeneration[J].Clin Ther,2007,29(9):1850-1861.
  • 3Joussen AM,Bornfeld N.The treatment of wet age-related macular degeneration[J].Dtsch Arztebl Int,2009,106(18):312-317.
  • 4Mulcahy MF,Benson AB Ⅲ.Bevacizumab in the treatment of colorectal cancer[J].Expert Opin Biol Ther,2005,5(7):997-1005.
  • 5Avery RL,Pieramic DJ,Rabena MD,et al.Intravitreal bevacizumab (avastin)for neovascular age-related macular degeneration[J].Ophthalmology,2006,113(3):363-372.
  • 6Chen CY,Wong TY,Heriot WJ,et al.Intravitreal bevacizumab (avastin)for neovascular age-related macular degeneration:a short study[J].Am J Ophthamol,2007,143(3):510-512.
  • 7Aisenbrey S,Ziemssen F,Volker M,et al.Intravitreal bevacizumab (avastin)for occult choroidal neovascularization in age-related macular degeneration[J].Graefes Arch Clin Exp Ophthalmol,2007,245(7):941-948.
  • 8Schmidt-Erfurth UM,Richard G,Augustin A,et al.Guidance for the treatment of neovascular age-related macular degeneration[J].Acta Ophthalmologica Scandinavica,2007,85(5):486-494.
  • 9Heiduschka P,Fietz H,Hofmeister S,et al.Tübingen bevacizumab study group:penetration of bevacizumab through the retina after intravitreal injection in the monkey[J].Invest Ophthalmol Vis Sci,2007,48(6):2814-2823.
  • 10Shahar J,Avery RL,Heilweil G,et al.Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin)[J].Retina,2006,26(3):262-269.

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部